11/28 Business Wire Health: Medical Devices News

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Business Wire Health: Medical Devices News Alliance HealthCare Services, Inc. Receives Requisite Consents to Amend Indentures November 27, 2009 at 5:33 pm NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Alliance HealthCare Services, Inc. (NYSE: AIQ), announced today that it has received tenders and consents on or prior to 5:00 p.m., New York City time on November 25, 2009 (the “Consent Date”) representing approximately 98.1% of the $300 million aggregate principal amount of its outstanding 7¼% Senior Subordinated Notes due 2012 (the “notes”). Alliance has received the requisite consents from holders of the notes to amend the n Global Health Partner AB: Communiqué from Extraordinary General Meeting November 27, 2009 at 10:05 am STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: The following resolutions were adopted today, 27 November, at the Extraordinary General Meeting of the shareholders of Global Health Partner (STO:GHP): • Warrants program for employees within the Global Health Partner Group The Board’s proposal concerning the issue of share warrants and free-of-charge share warrants, to be used for a warrants program directed at employees within the Global Health Partner Group, was adopted. The res Research and Markets: Medical Ultrasound Equipment - a Global Market Perspective November 27, 2009 at 7:58 am DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/363907/medical_ultrasound) has announced the addition of the "Medical Ultrasound Equipment - A Global Market Perspective" report to their offering. Since its introduction in the early 1950s, medical ultrasound has engulfed a major share of the medical imaging market. Advancement in new technologies such as 3-D and 4-D led to the development of innovative equipment that ensured improved image quality and cli Elekta: Invitation: Elekta's Interim Report May-October 2009/10 November 27, 2009 at 7:44 am STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: Elekta’s (STO:EKTAB) interim report for the first six months 2009/10 will be published on December 10 with the following schedule: The report will be published on December 10 at around 13.00 CET. Elekta will host a telephone conference 16.00-17.00 CET on December 10 with CEO Tomas Puusepp and CFO Håkan Bergström. To take part in the conference call, please dial in about ten minutes in advance. Swedish dial-in number: +46 (0)8 5 Research and Markets: The Medical Device Market in Croatia - Government Reforms Have Succeeded in Producing Modest Levels of Economic Growth November 27, 2009 at 6:28 am DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b30766/the_medical_device) has announced the addition of the "The Medical Device Market: Croatia" report to their offering. This in-depth medical device market report is ideal for executives wanting to understand the key drivers in medical markets and have access to a wealth of statistical data. Each report opens with an outlook section that provides analysis of the market, 5-year market forecasts, national GE医疗集团宣布在俄罗斯生产高科技医疗成像设备的计划‘��并在莫斯科开设培训中心 November 27, 2009 at 5:57 am 莫斯科--(BUSINESS WIRE)--通用电气公司（纽约证券交易所：GE）旗下GE医疗集团（GE Healthcare）与俄罗斯领先的医疗成像设备制造商医疗技术有限公司（Medical Technologies Limited，简称MTL）ߡ Media Files ViewMedia?mgid=206347&vid=2 (2 KB) GE医疗集团在莫斯科医疗康复中心安装俄罗斯首台通用电气高分辨率CT扫描仪 November 27, 2009 at 5:54 am 莫斯科--(BUSINESS WIRE)--(美国商业资讯)--通用电气公司(纳斯达克股票代码：GE)的下属部门GE医疗集团今天宣布，由Konstantin V. Lyadov教授领导的俄罗斯卫生部在位于莫斯科的医疗 Media Files ViewMedia?mgid=206346&vid=2 (2 KB) GE Healthcare gibt Pläne zur Herstellung hochtechnologischer Geräte zur medizinischen Bildgebung in Russland bekannt und eröffnet Schulungszentrum in Moskau November 27, 2009 at 5:48 am MOSKAU--(BUSINESS WIRE)--GE Healthcare, eine Geschäftseinheit der General Electric Company (NYSE:GE), und ein führender russischer Hersteller medizinischer Bildgebungstechnologie, Medical Technologies Limited (MTL), verkündeten heute eine strategische Partnerschaft zur Herstellung diagnostischer Bildgebungsprodukte in Russland im Rahmen der „healthymagination“-Strategie von GE. Das erste Produkt, das aus dieser Partnerschaft hervorgeht, ist das CT-System BrightSpeed Media Files ViewMedia?mgid=206347&vid=2 (2 KB) GE Healthcare annonce son intention de fabriquer de l'équipement d'imagerie médicale de haute technologie en Russie et ouvre un centre de formation à Moscou November 27, 2009 at 5:48 am MOSCOU--(BUSINESS WIRE)--GE Healthcare, une division de General Electric Company (NYSE : GE), et Medical Technologies Limited (MTL), un fabricant russe de premier plan de matériel d'imagerie médicale, ont annoncé aujourd'hui un partenariat pour la fabrication de produits d'imagerie médicale en Russie, à commencer par le système de tomographie assistée par ordinateur BrightSpeed™ Elite1, in line with GE’s healthymagination strategy. The partnership w Media Files ViewMedia?mgid=206347&vid=2 (2 KB) Sectra Signs Partnership Agreement with Leading Spanish Medical Distributor November 27, 2009 at 4:09 am STOCKHOLM--(BUSINESS WIRE)--Regulatory News: Sectra (STO:SECTB) has signed a partnership agreement with the Spanish company Fundación García Muñoz S.L. Founded in 1920, Fundación García Muñoz is a leading supplier of medical equipment and has an extensive customer base in both the private and public healthcare sectors in Spain. Through this partnership, Fundación García Muñoz has become a distributor of complete system for digital mammography includin Major European Regulatory Milestone in Cardiovascular Protection for MICARDIS® (telmisartan): Now Approved by the European Commission to Reduce the Risk of Cardiovascular (CV) Morbidity in High CV Risk Patients November 27, 2009 at 4:00 am INGELHEIM, Germany--(BUSINESS WIRE)--Boehringer Ingelheim announced today that the European Commission has approved MICARDIS® (telmisartan) for the reduction of cardiovascular morbidity in patients with: I. manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or, II. type 2 diabetes mellitus with documented target organ damage. MICARDIS® is the first treatment in its class to be approved for this indication. The EM Media Files ViewMedia?mgid=206363&vid=2 (2 KB)   This email was sent to billionlys.asdf1234@blogger.com.  Manage Your Account Don't want to receive this feed any longer? Unsubscribe here.